AAAAAA

   
Results: 1-7 |
Results: 7
Oral paclitaxel and concurrent cyclosporin A: Targeting clinically relevant systemic exposure to paclitaxel
Authors: Britten, CD Baker, SD Denis, LJ Johnson, T Drengler, R Siu, LL Duchin, K Kuhn, J Rowinsky, EK
Citation: Cd. Britten et al., Oral paclitaxel and concurrent cyclosporin A: Targeting clinically relevant systemic exposure to paclitaxel, CLIN CANC R, 6(9), 2000, pp. 3459-3468
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies
Authors: Ochoa, L Hurwitz, HI Wilding, G Cohen, D Thomas, JP Schwartz, G Monroe, P Petros, WP Ertel, VP Hsieh, A Hoffman, C Drengler, R Magnum, S Rowinsky, EK
Citation: L. Ochoa et al., Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies, ANN ONCOL, 11(10), 2000, pp. 1313-1322
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
Authors: Eckhardt, SG Baker, SD Britten, CD Hidalgo, M Siu, L Hammond, LA Villalona-Calero, MA Felton, S Drengler, R Kuhn, JG Clark, GM Smith, SL MacDonald, JR Smith, C Moczygemba, J Weitman, S Von Hoff, DD Rowinsky, EK
Citation: Sg. Eckhardt et al., Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies, J CL ONCOL, 18(24), 2000, pp. 4086-4097
DX-8951f, a hexacyclic camptothecin analog, on a daily times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies
Authors: Rowinsky, EK Johnson, TR Geyer, CE Hammond, LA Eckhardt, SG Drengler, R Smetzer, L Coyle, J Rizzo, J Schwartz, G Tolcher, A Von Hoff, DD De Jager, RL
Citation: Ek. Rowinsky et al., DX-8951f, a hexacyclic camptothecin analog, on a daily times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies, J CL ONCOL, 18(17), 2000, pp. 3151-3163
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors
Authors: Diab, SG Baker, SD Joshi, A Burris, HA Cobb, PW Villalona-Calero, RA Eckhardt, SG Weiss, GR Rodriguez, GI Drengler, R Kraynak, M Hammond, L Finizio, M Von Hoff, DD Rowinsky, EK
Citation: Sg. Diab et al., A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors, CLIN CANC R, 5(2), 1999, pp. 299-308
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies
Authors: Villalona-Calero, MA Petit, T Kuhn, J Cobb, P Kraynak, M Eckhardt, SG Drengler, R Simmons, C Santabarbara, P Von Hoff, DD Rowinsky, EK
Citation: Ma. Villalona-calero et al., A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies, CLIN CANC R, 5(11), 1999, pp. 3369-3378
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors
Authors: Eckhardt, SG Rizzo, J Sweeney, KR Cropp, G Baker, SD Kraynak, MA Kuhn, JG Villalona-Calero, MA Hammond, L Weiss, G Thurman, A Smith, L Drengler, R Eckardt, JR Moczygemba, J Hannah, AL Von Hoff, DD Rowinsky, EK
Citation: Sg. Eckhardt et al., Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors, J CL ONCOL, 17(4), 1999, pp. 1095-1104
Risultati: 1-7 |